Reopening of Black Sea a welcome relief, but while Ukraine remains volatile, latest data shows industry adapting
28.7.2022 10:44:00 EEST | Business Wire | Press release
With news of last week’s UN deal to reopen the Black Sea, allowing ocean grain shipments to resume from Ukraine, leading real-time supply chain visibility platform FourKites® released new data showing that agile shippers are finding ways of managing the volatile situation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005468/en/
FourKites data shows increased shipments to countries bordering Russia and Ukraine (Graphic: Business Wire)
Following Friday’s grain deal between Ukraine and Russia, FourKites expects grain shipments from Black Sea ports to resume within a few days. The same deal allows Russia to export fertiliser and other products not covered by international sanctions.
“My hope is that this agreement gives big shipping companies the confidence to resume operations in the region,” says Philippe Salles, FourKites’ VP Strategic Solutions (Ocean). “The next few weeks will be telling. But if things go well, this deal could be central to averting a worldwide food crisis. And despite the latest missile attack at the port of Odessa, indicating ongoing volatility in the region, our data indicates that shippers are well prepared for any contingency.”
Ukraine typically ships millions of tonnes of grain by ocean direct from its Black Sea ports to countries including Egypt, Indonesia and Bangladesh. The war effectively closed that route, as major shipping companies concluded it was too dangerous to operate in the Black Sea. Now, it is hoped, at least some of those shipments can resume.
“Our data for the last few weeks shows that logistics operators were already adapting to the situation in Ukraine,” says Salles. “Ukrainian shippers have been shifting to road and rail to move grain to sea ports outside the country, notably in Poland or via the Balkans to Adriatic ports such as Trieste and Rijeka.”
Shipments of all types to countries bordering Russia and Ukraine remain strong compared to the rest of Europe, where the 14-day average shipment volume is up 20% compared to 21 February, when the invasion began. At the same time, less than truckload (LTL) delays to Eastern Europe have decreased over the past few weeks, with delayed LTL shipments now only 15% higher than when the conflict began. This is down 48% month-on-month compared to mid-June, when LTL delays were as much as 33% higher than when the conflict began.
Prior to the UN deal, hundreds of thousands of tonnes of grain were destined to travel by longer land routes, which raised questions about whether there would be sufficient capacity to provide the thousands of additional truck journeys that would be needed.
“Ukrainian carriers are going full throttle to export grain and revive the country’s economic growth,” comments Maciej Mackowiak, FourKites’ Director, Carrier Marketing, Europe, who is based in Poland. “We are already seeing a lot of congestion on the Polish/Ukraine border because, since mid-July, the European Union has allowed Ukrainian road transport companies to make shipments without permits.”
Overall, moving goods into or out of Ukraine remains difficult. Shipment volumes to Ukraine have recovered slightly from their nadir in March, but are still 65% down on pre-war levels.
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005468/en/
Contact information
Scott Johnston
European PR Director, FourKites
+31 62 147 8442
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 11:00:00 EET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 11:00:00 EET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 11:00:00 EET | Press release
The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 11:00:00 EET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 10:15:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
